patent expirations News
Most Popular patent expirations Story
Few pharmas to profit off CV growth
The market for cardiovascular drugs will grow by $8 billion by 2018, but that doesn't mean drugmakers will necessarily profit. A Datamonitor study finds that because major CV meds are going off... Read more...
Latest Headlines
- March 5, 2010
- March 4, 2010
- February 10, 2010
- February 4, 2010
- January 27, 2010
- December 10, 2009
- December 10, 2009
- December 9, 2009
- November 20, 2009
- November 17, 2009
- October 26, 2009
- September 18, 2009
- September 16, 2009
- May 29, 2009
- May 19, 2009
- April 15, 2009
- April 6, 2009
- April 6, 2009
- March 19, 2009
- January 22, 2009
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
